ALG2 and congenital myasthenic syndrome: Mutations in four other glycosylation genes (ALG2, ALG14, DPAGT1 and GFPT1) are known to lead to the development of CMS, and the symptoms of other glycosylation-CMS patients are similar to the symptoms of Case 1.